



Marcy l'Etoile, France – November 3, 2009 — A world leader in the field of *in vitro* diagnostics, bioMérieux has appointed Alain Pluquet to the newly created position of Chief Technology Officer (CTO).

In bioMérieux's Research and Development, Alain Pluquet's key mission will be enhancing the company's technology portfolio through in-house programs, external research partnerships and targeted technology acquisitions. His deep knowledge of the public research sector in France, and especially the CEA (French Atomic Energy Commission), will further strengthen bioMérieux's ties with these institutions for a variety of joint research projects in the company's technology strategy roadmap.

"bioMérieux's number one priority is to help clinicians around the world improve patient care, by drastically reducing bacterial infection diagnostic time-to-results. We are creating this new Chief Technology Officer position to look at technologies that we have never contemplated before with the goal of bringing major innovation to public health", stated Stéphane Bancel, Chief Executive Officer of bioMérieux. "We are very pleased to welcome Alain, whose experience, leadership and outside-the-box thinking will be invaluable as we reinvent our core technologies to build the diagnostic tools of the future."

Alain Pluquet has a Ph.D. in nuclear physics from Fermilab in the U.S. and the CEA. He holds a Master degree in Fields-Particles-Matter from the French engineering school, Ecole Polytechnique and the University of Paris VI, VII, XI. Mr. Pluquet has worked in the CEA network since 1994. Before joining bioMérieux, he was Head of the Signal and Capturing Technology Department at the CEA LIST (Laboratory for system and technology integration).

About bioMérieux

Innovative diagnostics to improve public health

A world leader in the field of *in vitro* diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2008, revenues reached €1.111 billion with 84% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479). Other information can be found at www.biomerieux.com.

Contacts

Investor Relations

bioMérieux

Isabelle Tongio
Tel: + 33 (0)4 78 87 22 37
investor.relations@eu.biomerieux.com

LT Value

Nancy Levain
Tel: +33 (0)1 44 50 39 30
nancy.levain@ltvalue.com

Media Relations

bioMérieux

Koren Wolman-Tardy
Tel: + 33 (0)4 78 87 20 08
media@eu.biomerieux.com

Fleishman Hillard

Tim Baker
Tel: + 1 216 338-8086
tim.baker@fleishman.com

Image Sept

Laurence Heilbronn
Tel: + 33 (0)1 53 70 74 64
lheilbronn@image7.fr

Tiphaine Hecketsweiler
Tel: + 33 (0)1 53 70 74 59
thecketsweiler@image7.fr